Nj\u00eb vaksin\u00eb e re bazuar n\u00eb teknologjin\u00eb mRNA ka ndaluar rikthimin e kancerit t\u00eb l\u00ebkur\u00ebs tek pacient\u00ebt gjat\u00eb nj\u00eb prove, duke p\u00ebrfaq\u00ebsuar nj\u00eb moment potencialisht vendimtar n\u00eb trajtimin e kancerit. BBC shkruan se vaksina, e zhvilluar nga kompanit\u00eb farmaceutike Merck & Co ose MSD, dhe Moderna, iu dha pacient\u00ebve me melanom\u00eb me rrezik t\u00eb lart\u00eb, nj\u00eb lloj kanceri t\u00eb l\u00ebkur\u00ebs.<\/p>\n
Ekspert\u00ebt e kancerit thon\u00eb se ky \u00ebsht\u00eb nj\u00eb p\u00ebrparim, por theksojn\u00eb kujdesin pasi rezultatet e plota nuk jan\u00eb publikuar ose rishikuar nga koleg\u00ebt. Vaksina, e quajtur Intismeran, u dha n\u00eb kombinim me Keytruda, nj\u00eb ila\u00e7 imunoterapie q\u00eb p\u00ebrdoret tashm\u00eb n\u00eb trajtimin e kancerit.<\/p>\n
Krahasuar me marrjen e Keytrud\u00ebs ve\u00e7mas, kompanit\u00eb than\u00eb se marrja e ila\u00e7it dhe vaksin\u00ebs s\u00eb bashku rriti ndjesh\u00ebm koh\u00ebn q\u00eb pacient\u00ebt mbet\u00ebn pa kancer dhe zvog\u00ebloi rrezikun e p\u00ebrhapjes s\u00eb s\u00ebmundjes n\u00eb organe t\u00eb tjera.<\/p>\n
N\u00eb faz\u00ebn e tret\u00eb t\u00eb studimit u p\u00ebrfshin\u00eb m\u00eb shum\u00eb se 1,000 pacient\u00eb q\u00eb kishin melanom\u00eb n\u00eb faz\u00ebn e dyt\u00eb, t\u00eb tret\u00eb ose t\u00eb kat\u00ebrt me rrezik t\u00eb lart\u00eb \u2013 q\u00eb do t\u00eb thot\u00eb se ata kishin tumore t\u00eb m\u00ebdha n\u00eb nj\u00eb zon\u00eb specifike deri te kanceri q\u00eb ishite p\u00ebrhapur tashm\u00eb n\u00eb pjes\u00eb t\u00eb tjera t\u00eb trupit.<\/p>\n
P\u00ebr t\u00eb krijuar k\u00ebt\u00eb vaksin\u00eb t\u00eb re, shkenc\u00ebtar\u00ebt p\u00ebrdor\u00ebn teknologjin\u00eb e ARNi-s\u00eb \u2013 e cila u p\u00ebrdor p\u00ebr disa vaksina kund\u00ebr Covid-19 \u2013 p\u00ebr t\u00eb synuar mutacione specifike brenda qelizave kancerogjene duke hequr kirurgjikalisht nj\u00eb pjes\u00eb t\u00eb vog\u00ebl t\u00eb tumorit t\u00eb nj\u00eb pacienti dhe m\u00eb pas duke sekuencuar ADN-n\u00eb e tij. Rezultati \u00ebsht\u00eb nj\u00eb injeksion i personalizuar kund\u00ebr kancerit, i cili \u00ebsht\u00eb specifik p\u00ebr tumorin e pacientit dhe udh\u00ebzon sistemin imunitar t\u00eb njoh\u00eb dhe sulmoj\u00eb \u00e7do qeliz\u00eb tumorale q\u00eb mbetet.<\/p>\n
T\u00eb dy kompanit\u00eb po testojn\u00eb vaksina t\u00eb tjera t\u00eb ngjashme t\u00eb personalizuara p\u00ebr kancerin e mushk\u00ebrive, fshik\u00ebz\u00ebs dhe veshkave. Dr. Talisia Quallo, drejtuese e parandalimit dhe zbulimit t\u00eb hersh\u00ebm n\u00eb Cancer Research UK, tha se hulumtimi \u201ctregon premtime\u201d, por tha se t\u00eb dh\u00ebnat e nd\u00ebrmjetme ende duhet t\u00eb rishikohen plot\u00ebsisht.<\/p>\n
T\u00eb dy kompanit\u00eb po testojn\u00eb vaksina t\u00eb tjera t\u00eb ngjashme t\u00eb personalizuara p\u00ebr kancerin e mushk\u00ebrive, fshik\u00ebz\u00ebs dhe veshkave. Dr. Talisia Quallo, drejtuese e parandalimit dhe zbulimit t\u00eb hersh\u00ebm n\u00eb Cancer Research UK, tha se hulumtimi \u201ctregon premtime\u201d, por tha se t\u00eb dh\u00ebnat e nd\u00ebrmjetme ende duhet t\u00eb rishikohen plot\u00ebsisht.<\/p>","protected":false},"excerpt":{"rendered":"
Nj\u00eb vaksin\u00eb e re bazuar n\u00eb teknologjin\u00eb mRNA ka ndaluar rikthimin e kancerit t\u00eb l\u00ebkur\u00ebs tek pacient\u00ebt gjat\u00eb nj\u00eb prove, duke p\u00ebrfaq\u00ebsuar nj\u00eb moment potencialisht vendimtar n\u00eb trajtimin e kancerit. BBC shkruan se vaksina, e zhvilluar nga kompanit\u00eb farmaceutike Merck & Co ose MSD, dhe Moderna, iu dha pacient\u00ebve me melanom\u00eb me rrezik t\u00eb lart\u00eb, […]<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-97729","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/zennihost.com\/test\/wp-json\/wp\/v2\/posts\/97729","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/zennihost.com\/test\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/zennihost.com\/test\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/zennihost.com\/test\/wp-json\/wp\/v2\/comments?post=97729"}],"version-history":[{"count":0,"href":"https:\/\/zennihost.com\/test\/wp-json\/wp\/v2\/posts\/97729\/revisions"}],"wp:attachment":[{"href":"https:\/\/zennihost.com\/test\/wp-json\/wp\/v2\/media?parent=97729"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/zennihost.com\/test\/wp-json\/wp\/v2\/categories?post=97729"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/zennihost.com\/test\/wp-json\/wp\/v2\/tags?post=97729"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}